Targeting RNA as an approach for treating retinal disease

Restore sight by using RNA therapies * Retorna * Project number: 101073316 * HORIZON-MSCA-2021-DN-01 * European Research Executive Agency *

Today, vision impairment up to total blindness represents an increasing global problem

Icono de un ojo animado

This problem leads to a significant social and economic impact on affected patients and society as a whole.

Despite the advancing of knowledge on their genetic basis, there is no effective cure for retinal diseases to date and therefore there is an urgent need to fill this gap. Funded by the Marie Skłodowska-Curie Actions programme, the RETORNA project aims to find treatment for RD based on RNA therapy.

Icono de un ojo animado

Research objectives

The main scientific aim is to observe changes in miRNA/mRNA profile of affected cells in retinal degenerations and correct those using different molecules, such as miRNA mimics, RNA-aptamers, and antisense oligonucletides.

RETORNA in numbers

€ 2.568.425,56
EU Contribution
1 February 2023

Project starting date

31 January 2027
Project end date
48 months


The objective is to create RNA profiles for different RD and identify several potential targets that will be used as therapeutic approaches.

Latest news & updates about the project

Foto equipo RETOS
RETOS lab research accepted for publication
DC10 open position at UCV – Valencia
Activities organized by Cuenca lab in the Universidad de Alicante campus
European Researchers’ Night (and day) edition 2023

Learn more about RETORNA

Get in contact with us